Berlin, 26.07.2024 – KD Pharma Group, a leading CDMO in pharmaceutical and nutritional lipids, and dsm-firmenich, an innovator in nutrition, health and beauty, have announced the sale of dsm-firmenich's marine lipids business to KD Pharma Group in exchange for a minority stake in the enlarged KD Pharma Group. dsm-firmenich's marine lipids fish oil omega-3 business serves the food & beverage, dietary supplement and pharmaceutical markets and includes the MEG-3® brand and production facilities in Piura, Peru and Mulgrave, Canada.
A CMS team led by Patrick Lühr provided comprehensive legal advice to capiton's portfolio company O³ Holding GmbH, the parent company of the KD Pharma Group, on the reinvestment by dsm-firmenich in the KD Pharma Group and the formation of the joint venture.
The transaction will create a well-equipped player in marine lipids by combining the two companies and their respective expertise with the scale of dsm-firmenich's Piura and Mulgrave sites and the high concentration capability of the KD Pharma group company. The enlarged KD Pharma Group company will benefit from the expansion into a significantly wider product range and customisation opportunities supported by increased manufacturing capacity. dsm-firmenich will continue to offer MEG-3® fish oils for the early life nutrition markets as well as MEG-3® powders. The transaction is expected to close towards the end of 2024 and is subject to customary regulatory approvals.
CMS Germany
Dr Eva Annett Grigoleit, Partner
Patrick M. Lühr, Lead Counsel
Anna Schäfer, Senior Associate
Dr Maximilian Koch, Senior Associate
Dr Florian Wimmer, Associate
Dr Hanna Heimrath, Associate
Olena Gaus, Senior Legal Specialist, all Corporate/M&A
Dr Martin Friedberg, Partner, Tax
Sylle Schreyer-Bestmann, Counsel, Intellectual Property
Press Contact
presse@cms-hs.com
